# Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

> **NCT00006219** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** clarithromycin
- **DRUG:** prasterone

## Key facts

- **NCT ID:** NCT00006219
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** — (—)
- **Last updated:** 2011-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006219, "Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00006219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*